Læknablaðið - 15.09.1999, Qupperneq 31

LÆKNABLAÐIÐ 1999; 85
697
Aðalveikleiki þessarar rannsóknar er aftur-
skyggnt snið hennar. Vegna þessa er notkun
lyfja eftir innlögn ekki tilviljunarkennd heldur
háð mati mismunandi lækna á ástandi sjúklings
hverju sinni. Þannig gætu þeir sem veikastir
eru hafa fengið aðra meðferð en þeir sem hafa
minni einkenni. Skráning áhættuþátta gæti
einnig verið nákvæmari hjá minna veikum
sjúklingum þar sem lengri tími gefst til viðtals
og skoðunar. Þá vantar heildarfjölda þeirra sem
deyja af völdum kransæðastíflu á upptöku-
svæði spítalanna og á landinu öllu svo hægt sé
að meta heildardánarhlutafall kransæðastíflu.
Ymsum grundvallarspurningum um áhrif
breyttrar meðferðar kransæðastíflu á horfur
hefur verið svarað með þessari rannsókn.
Margt er þó enn óþekkt. Ahrif áhættuþátta á
horfur sjúklinga með kransæðastíflu hafa ekki
verið rannsökuð á framskyggnan máta en tíðni
áhættuþátta hjá íslenskum hjartasjúklingum og
áhrif þeirra á uppkomu kransæðasjúkdóms
meðal íslendinga er þekkt úr rannsóknum
Hjartaverndar.
Þakkir
Eftirtöldum aðilum er þakkað: Guðmundi
Oddssyni yfirlækni hjartadeildar Sjúkrahúss
Reykjavíkur, Arna Kristinssyni yfirlækni
hjartadeildar Landspítalans, Nikulási Sigfús-
syni, Ugga Agnarssyni og Helga Sigvaldasyni
hjá Hjartavernd, starfsfólki skjalasafna og
tölvudeilda Sjúkrahúss Reykjavíkur og Land-
spítalans og læknariturum lyflækningadeildar
Sjúkrahúss Reykjavíkur. Rannsóknin var styrkt
með framlagi úr Vísindasjóði Borgarspítalans.
HEIMILDIR
1. Second Intemational Study on Infarct Survival Collabor-
ative Group. Randomised trial of intravenous streptokinasi,
oral aspirin, both or neither among 17187 cases of suspec-
ted myocardial infarction. ISIS-2. Lancet 1988; 336: 827-
30.
2. The RISC Group. Risk of myocardial infarction and death
during treatment with low dose aspirin and intravenous
heparin in men with unstable coronary artery disease.
Lancet 1990; 336: 827-30.
3. First Intemational Study on Survival Collaborative Group.
Randomised trial of intravenous atenolol among 16027
cases of suspected acute myocardial infarction: ISIS-1.
Lancet 1986; 2: 57-66.
4. The MIAMI trial research group. Metoprolol in acute myo-
cardial infarction (MIAMI). Eur Heart J 1985; 5: 199-226.
5. Gmppo italiani per lo studio della streptochinase nell’
infarcto myocardico (GISSI): Effectiveness of intravenous
thrombolytic treatment in acute myocardial infarction.
Lancet 1986; I: 397-401.
6. The GUSTO investigators. An intemational randomised
trial comparing four thrombolytic strategies for acute
myocardial infarction. N Engl J Med 1993; 329: 673-82.
7. CONSENSUS Trial Study Group. Effect of enalapril on
mortality in severe congestive heart failure. Results of the
cooperative North-Scandinavian enalapril survival study
(CONSENSUS). N Engl J Med 1987; 316: 678-84.
8. The Acute Infarction Ramipril Efficiacy (AIRE) study in-
vestigators. Effects of ramipril on mortality and morbidity
of survivors of acute myocardial infarction with clinical
evidence of heart failure. Lancet 1993; 342: 821-8.
9. Randomised trial of cholesterol lowering in 4444 patients
with coronary heart disease: the Scandinavian Simvastatin
Survival Study (4S). Lancet 1994; 344: 1383-9.
10. Buring JE, Glynn RJ, Hennekens CH. Calcium channel
blockers and acute myocardial infarction: a hypothesis
formulated but not yet tested. JAMA 1995; 274: 654-5.
11. Davies RF, Goldberg AD, Forman S, Pepine CJ, Knattemd
GL, Geller N, et al. Asymptomatic Cardiac Ischemia Pilot
(ACIP) Study Two-Year Follow-up: Outcomes of Patients
Randomized to Initial Strategies of Medical Therapy Versus
Revascularization. Circulation 1997; 95: 2037-43.
12. GUSTO-IIb Angioplasty Substudy Investigators. A clinical
trial comparing primary angioplasty with tissue plasmino-
gen activator for acute myocardial infarction. N Engl J Med
1997; 336: 1621-8.
13. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW,
O’Keefe J, et al. The Primary Angioplasty in Myocardial
Infarction Study Group. A comparison of immediate
angioplasty with thrombolytic therapy for myocardial
infarction. N Engl J Med 1993; 328: 673-9.
14. Agnarsson U, Sigfússon N, Guðmundsdóttir II, Stefáns-
dóttir I. Bráð kransæðastífla á íslandi 1982-1986. Lækna-
blaðið 1996; 82: 276-85.
15. Chambless L, Keil U, Dobson A, Mahonen M, Kuulasmaa
K, Rajakangas AM, et al. Population versus clinical view of
case mortality from acute coronary heart disease: results
from the WHO MONICA Project 1985-1990. Multinational
MONItoring of trends and Determinants in Cardiovascular
Disease. Circulation 1997; 96: 3849-59.
16. Salomaa VV, Lundberg V, Agnarsson U, Radisauskas R,
Kirchhoff M, Wilhelmsen L. Fatalities from myocardial
infarction in Nordic countries and Lithuania. The MONICA
Investigators. Eur Heart J 1997; 18: 91-8.
17. Bjömsdóttir US, Thorlacius S, Jónsson Á, Lárusson G.
Kransæðastífla á Landakotsspítala 1981-1985. Læknablað-
ið 1988; 74: 241-3.
18. McGovem PG, Herlitz J, Pankow JS, Karlsson T, Dellborg
M, Shahar E, et al. Comparison of medical care and 12
month mortality of hospitalised patient with acute myo-
cardial infarction in Minneapolis/St. Paul, Minnesota,
United States of America and Göteborg Sweden. Am J
Cardiol 1997; 80: 557-62.
19. Jónsson JJ, Óskarsson H, Þorgeirsson Gu, Þorgeirsson Ge,
Eyjólfsson Ó, Harðarson Þ. Segaleysandi meðferð við bráðri
kransæðastíflu. Árangur meðferðar hjá fyrstu þrjátfu og
þremur íslensku sjúklingunum. Læknablaðið 1986; 72: 191-8.
20. Sigfússon N, Sigvaldason H, Steingrimsdóttir L, Guð-
mundsdóttir II, Stefánsdóttir I, Thorsteinsson TH, et al.
Decline in ischemic heart disease in Iceland and change in
risk factor levels. BMJ 1991; 302: 1371-5.
21. Madsen JK, Pedersen F, Nielsen H, Jensen GV, Hansen JF.
Improved long term prognosis in elderly patients with acute
myocardial infarction after the introduction of intravenous
thrombolytic therapy. Scand Cardiovasc J 1998; 32: 365-
70.
22. Gottlieb SS, McCarter RJ, Vogel RA. Effect of Beta-Blockade
on Mortality among High-Risk and Low-Risk Patient after
Myocardial Infarction. N Engl J Med 1998; 339:489-97.
23. Buring JE, Glynn RJ, Hennekens CH. Calcium channel
blockers and acute myocardial infarction: a hypothesis
formulated but not yet tested. JAMA 1995; 274: 654-5.
24. Sigurðsson EL, Jónsson JS, Þorgeirsson G. Hvemig er kól-